This website is for Israeli Healthcare Professionals only
Evaluation of PREEMPT Fixed-dose, Fixed-site, and Follow-The-Pain Treatment Paradigms in the PREDICT Study
Real-World Safety and Efficacy of 156-195U OnabotulinumtoxinA in Participants with Chronic Migraine: Results from the REPOSE Study
Consecutive Headache-Free Days with OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: A Pooled PREEMPT Analysis
Real-World Evidence for Control of Patients with Chronic Migraine Who Received Calcitonin Gene-Related Peptide Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment
You are now leaving the AbbVie Pro Portal and being re-directed to an external website which is not under the control of AbbVie. AbbVie is not responsible for content of any such site or any further links from such site.
Do you wish to continue?